Tenaya Therapeutics (TNYA) Accumulated Expenses (2020 - 2026)

Tenaya Therapeutics' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $6.0 million for Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 4.19% year-over-year to $6.0 million in Q1 2026; TTM through Mar 2026 was $6.0 million, a 4.19% decrease from a year earlier, with the FY2025 full-year figure at $8.8 million, up 9.96% from the prior year.
• Accumulated Expenses slipped to $6.0 million in Q1 2026 per TNYA's latest filing, from $8.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $12.8 million in Q4 2023 and bottomed at $6.0 million in Q1 2026.
• The 5-year median for Accumulated Expenses is $8.4 million (2022), against an average of $8.5 million.
• Across the five-year window, Accumulated Expenses soared 202.2% in 2022 and plunged 37.15% in 2024, its largest moves.
• Year by year, Accumulated Expenses stood at $10.7 million in 2022, then climbed by 19.88% to $12.8 million in 2023, then plunged by 37.15% to $8.0 million in 2024, then advanced by 9.96% to $8.8 million in 2025, then plunged by 31.75% to $6.0 million in 2026.
• Per Business Quant, the three latest TNYA Accumulated Expenses figures stand at $6.0 million (Q1 2026), $8.8 million (Q4 2025), and $7.4 million (Q3 2025).